PlainPharmaWatch

CMS Open Payments · Program Year 2024

GenMark Diagnostics, Inc.

GenMark Diagnostics, Inc. reported $163,365.66 across General Payments, Research, and Ownership to 8 physicians and teaching hospitals across 15 transactions.

See the rankings → How this is sourced
$163.4K
All-tracks total
15
Transactions
8
Recipients
−$27.3K
General Payments vs PY2023

GenMark Diagnostics, Inc. reported $163,365.66 across all CMS Open Payments tracks (General + Research + Ownership) to 8 physicians and teaching hospitals in Program Year 2024 - ranking #1062 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $18,078.19, averaging $20.4K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer genmark-diagnostics-inc GenMark Diagnostics, Inc.

$163.4K · #1062/1,925 · 0.0% industry · PY2024

  • TOT $163.4K
  • RANK #1062
  • SHARE 0.0%
  • TXN 15
  • RCP 8
  • CAT 2
  • GEN $18.1K
  • ΔGEN −$27.3K
  • TOP1 38.7%
  • PY 2024

Volume peers

Nearest volume peer: Acist Medical Systems, Inc. ($163.3K)

Avertix Medical, Inc$164.0KNeos Therapeutics, LP$163.6KGenMark Diagnostics, Inc. (t…$163.4KAcist Medical Systems, Inc.$163.3KFresenius USA Manufacturing,…$163.1K
All-tracks payment totals near GenMark Diagnostics, Inc. (CMS Open Payments PY2024)

GenMark Diagnostics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

GenMark Diagnostics, Inc.'s CMS-reported General Payments decreased by $27.3K (−60.1%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: GENMARK DIAGNOSTICS, INC.PY2023: GENMARK DIAGNOSTICS, INC.PY2024: GenMark Diagnostics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$45.4KPY2024$18.1K
PY2023
$45,354.59
PY2024
$18,078.19

What the Data Shows for GenMark Diagnostics, Inc.

$163,365.66: that is what GenMark Diagnostics, Inc. reported in payments to 8 physicians and teaching hospitals during Program Year 2024, spread across 15 transactions ($10.9K per transaction, $20.4K per recipient). The company sits at rank #1062 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Compensation for Services Other Than Consulting" leads the 2-category general-payment breakdown below at $17.6K (97.4% of General Payments, 7 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 2 types of general payments, GenMark Diagnostics, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $17.6K - 97.4% of General Payments.

How GenMark Diagnostics, Inc. divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$17.6K2. Travel and Lodging$468.19
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $17.6K 7
Travel and Lodging $468.19 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $18,078.19 (100.0%) of $18,078.19 in this company's General Payments records across 4 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for GenMark Diagnostics, Inc.

The five named recipients with the highest reported General Payments from this company

Bobbi Pritt$7.0KLarissa May$5.5KWilliam Stauffer$3.5KRojelio Mejia$2.1K
  1. 1

    Bobbi Pritt

    $7,000.00 across 3 reported transactions

  2. 2

    Larissa May

    $5,478.19 across 2 reported transactions

  3. 3

    William Stauffer

    $3,500.00 across 2 reported transactions

  4. 4

    Rojelio Mejia

    $2,100.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as GenMark Diagnostics, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about GenMark Diagnostics, Inc..

Olea Medical

HHI 2931

Evologics LLC

HHI 2920

ProgenaCare Global, LLC

HHI 2943

Renalytix AI, Inc.

HHI 2909

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with GenMark Diagnostics, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download GenMark Diagnostics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.